ArticleWorld journal of clinical cases2022
Endoscopic ultrasound radiofrequency ablation of pancreatic insulinoma in elderly patients: Three case reports.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Pooled it
- Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Recent Development of Endo-hepatology.DEN open · 2027Review
- Treatment of Hepatocellular Carcinoma Using Endoscopic Ultrasound-guided Radiofrequency Ablation: A Case Series.DEN open · 2026Article
- Endoscopic Ultrasound-Guided Radiofrequency Ablation in the Management of Pancreatic Tumors: A Comprehensive Systematic Review and Meta-Analysis.Gastro hep advances · 2026Review
- Endoscopic-Ultrasound-Guided Radiofrequency Ablation for Pancreatic Tumors.Journal of clinical medicine · 2025Review
- Review
- EUS-Guided Radiofrequency Ablation Therapy for Pancreatic Neoplasia.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- Review
- Approaching Small Neuroendocrine Tumors with Radiofrequency Ablation.Diagnostics (Basel, Switzerland) · 2023Review
- Impact of endoscopic ultrasound-guided radiofrequency ablation in managing pancreatic malignancy.World journal of gastrointestinal surgery · 2023Review
- Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies.World journal of gastroenterology · 2023Review
- Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.World journal of gastroenterology · 2022Review
- Radiofrequency ablation for pancreatobiliary disease: an updated review.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) has recently been proposed as a local treatment for functional pancreatic neuroendocrine neoplasms in patients unfit for surgery, in order to obtain clinical syndrome regression. Data on the safety and long-term effectiveness of this approach are scarce, and EUS-RFA procedures are not standardized. CASE SUMMARY: The present case series reports 3 elderly patients with a pancreatic insulinoma and comorbidities, locally treated by EUS-guided RFA with clinical success in terms of hypoglycemic symptoms. RFA procedures were performed during deep sedation, under EUS control with a 19 G needle, an electrode 5-mm in size at a power of 30 W and multiple RFA applications during the same session in order to treat the whole area of the lesions. Immediate relief of symptoms was evident in 2 patients after the first EUS-RFA, while in the third patient a second endoscopic treatment was needed. All 3 patients are symptom-free without need of medications after 24 mo of follow-up with imaging follow-up showing no disease recurrence. A single adverse event of intraprocedural bleeding occurred, which was successfully treated endoscopically.
conclusionEUS-RFA represents an effective and safe alternative to surgery for the treatment of insulinomas in elderly patients at high surgical risk. However, larger multicenter studies with longer follow-up are needed in order to better assess its safety and clinical success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.